Mar. 12 at 7:36 PM
$ALVO Outlook for 2026 from their Dec Biz Update:
→ Following successful completion of the
offering the amount raised is expected to fund
the company through to cash flow positivity in
Q4 2026
→ Anticipate total revenues in the range of
$650
700 million in 2026, reflecting continued
double-digit sales growth
→ Adj.EBITDA expected to increase to
$180-220
million, supported by higher volumes of
commercialized products and launches of
newly approved products in Europe, Japan and
the UK
→ Alvotech assumes to receive U.S. approval by
late 2026 for the 4 Biologics License
Applications active with the FDA, with
minimum impact on the topline, and remains
optimistic to be the first or among the first with
approved biosimilars to Simponi® and Simponi
Aria® in the US
→ The lower end of the revenue range assumes
the possibility of further delay of pending FDA
approvals
